摘要
Baxdrostat 為新型選擇性醛固酮合成酶抑制劑,透過抑制CYP11B2 降低醛固酮生成而不影響皮質醇,為口服每日一次,常用劑量1–2 mg。二期BrigHTN 試驗顯示其具劑量依賴性降壓效果,2 mg 組平均收縮壓較安慰劑額外變化–11.0 mmHg (p < 0.001),且耐受性良好。三期BaxHTN 試驗則顯示,口服baxdrostat 2 mg 每日一次,在12 週相較安慰劑額外坐姿收縮壓變化為–9.8 mmHg (95% confidence interval [CI]–12.6 to –7.0; p < 0.001),且多數次族群分析結果一致,突顯其臨床意義。
安全性方面,主要關注血鉀與血鈉變化,以及治療早期estimated glomerular filtration rate (eGFR) 輕度下降,但多屬可逆可控,未見藥品相關死亡或嚴重心血管不良事件。整體而言,baxdrostat 兼具降壓療效與良好耐受性,對spironolactone 不耐受或高血鉀風險病人提供新選擇,目前baxdrostat 已進入新藥申請審查階段,美國食品藥物管理局已受理並給予優先審查。
ABSTRACT
Baxdrostat is a novel, selective aldosterone synthase inhibitor that lowers aldosterone synthesis by inhibiting CYP11B2 without affecting cortisol production. It is administered orally once daily, with typical doses of 1–2 mg. In the phase 2 BrigHTN trial, baxdrostat demonstrated a dose-dependent antihypertensive effect; at week 12, the placebo-corrected change in seated systolic blood pressure (SBP) in the 2 mg group was –11.0 mmHg (p < 0.001), with good overall tolerability. In the phase 3 BaxHTN trial, baxdrostat 2 mg once daily produced an additional placebo-corrected seated SBP change of –9.8 mmHg at week 12 versus placebo (95% confidence interval [CI] –12.6 to –7.0; p < 0.001), and effects were generally consistent across most subgroups.
Safety findings mainly involved changes in serum potassium and sodium, as well as a mild, early decline in estimated glomerular filtration rate (eGFR), but these were generally reversible and manageable. No medication-related deaths or major cardiovascular adverse events were reported.
Overall, baxdrostat demonstrated both antihypertensive efficacy and good tolerability, representing a promising therapeutic option particularly for patients who are intolerant to spironolactone or at elevated risk of hyperkalemia. The medication has entered the regulatory review phase, with the U.S. Food and Drug Administration accepting the New Drug Application (NDA) under priority review.
Submitted for publication: 2025.10.02; Accepted for publication: 2026.01.06